Seraseq™ Circulating Tumor DNA-I Reference Material (WT)
Seraseq Circulating Tumor DNA-I Reference Material (WT) is manufactured from human genomic DNA formulated in a commutable matrix (simulated plasma). The product is formulated with a 0% (WT) allele frequency as determined by digital PCR (not detected) for a set of 9 mutations (single-nucleotide variants in addition to insertion/deletions).
- Proprietary stabilization technology in defined MatriBase matrix
- GM24385 'wild-type' background yields no extraneous mutation artifacts
- Single-tube 5mL format contains 60ng of extractable nucleic acid
- Manufactured in cGMP compliant, ISO 9001 and ISO 13485 certified facilities
Seraseq Circulating Tumor DNA-I Reference Material (WT) - LIst of Mutations Tested
This product was tested and found NEGATIVE (wild-type) for the following 9 mutations.
The Seraseq Circulating Tumor DNA-I (WT) Reference Material is formulated for use with targeted next-generation sequencing (NGS) assays, real-time quantitative PCR (qPCR) or digital PCR (dPCR) assays that screen for circulating tumor DNA (ctDNA) in a cell-free plasma sample. The Seraseq Circulating Tumor DNA-I (WT) Reference Material is intended as a quality material for translational oncology researchers, assay developers, and clinical pathology laboratories, and monitors sample purification, library preparation, and sequencing (if using an NGS-based assay), and detection performance.
For research use only. Not for use in diagnostic procedures.